Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences

키워드

참고문헌 (11)

1. Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", Hepatology, 78, pp.1966~1986 (2023)
2. Yoon EL, "Waiting for the changes after the adoption of steatotic liver disease", Clin Mol Hepatol, 29, pp.844~850 (2023)
3. Iwaki M, "Prognosis of biopsy-confirmed MASLD : a sub-analysis of the CLIONE study", Clin Mol Hepatol, 30, pp.225~234 (2024)
4. Fujii H, "Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients : A multicenter registry-based cohort study", Clin Gastroenterol Hepatol, 21, pp.370~379 (2023)
5. Ko E, "Risk factors in nonalcoholic fatty liver disease", Clin Mol Hepatol, 29(Suppl), pp.S79~S85 (2023)
6. Lee HH, "Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease", Gut, 73, pp.533~540 (2024)
7. Fan X, "Systemic metabolic Abnormalities : Key drivers of complications and mortality in MASLD", J Hepatol (2024)[DOI]
8. Younossi ZM, "Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease", J Hepatol (2024)[DOI]
9. Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
10. Yoon EL, "Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology", Clin Mol Hepatol, 29, pp.371~373 (2023)
11. Golabi P, "Nonalcoholic fatty liver disease(NAFLD)and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States", Metabolism, 146, pp.155642~ (2023)

관련 논문AI추천